Quick answer
Read a BPC-157 certificate as a record of one lot, not a quality guarantee. Match the lot string to the vial, find the method and chromatogram behind the purity figure, ask what “identity” was actually measured, and note the sequence-specific risks: a Pro-Pro-Pro run, an Asp-Asp pair and the salt form. The product page lists ≥98% HPLC purity; the COA page shows which lot certificates are published. Supplied for laboratory research use only.
BPC-157 is one of the best-known short research peptides, and its certificate of analysis is a good teaching document because the molecule is simple on paper and awkward in practice. It has fifteen residues, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, as listed on the BPC-157 product page, which supplies it as a 10 mg lyophilized powder with a ≥98% HPLC specification. This article reads a BPC-157 certificate field by field: what each entry is, which BPC-157-specific features make it worth a second look, and which gaps a laboratory should close for itself. It is written for laboratory research use only.
For the compound itself, see the BPC-157 research overview. For where certificates fit among other purchasing checks, see where to buy BPC-157 for research. This guide concentrates on the document.
The fields, in the order they matter
A certificate is a record of one analysis of one lot. Its value depends on whether you can tie it to your vial and whether it states how the number was obtained. The table lists the fields and what each one can and cannot establish.
| Field | What it establishes | What to look for in BPC-157 specifically |
|---|---|---|
| Compound name and sequence | The intended molecule | The fifteen-residue sequence above, with no extra tags or salt names that suggest a different form |
| Lot or batch number | Traceability | Identical to the string on your vial label |
| Analytical test date | When the analysis happened | A date that fits with the manufacturing and shipping timeline |
| HPLC purity | Share of UV signal in the main peak | The wavelength and gradient; whether the main peak is symmetric |
| Chromatogram | The actual separation | Peak shape, shoulders, the number and position of minor peaks |
| Identity / mass | The main species has the expected mass | Observed mass in agreement with the calculated mass for the full sequence |
| Supplied form and storage | Physical state and handling | Lyophilized powder; refrigerate 2–8 °C, −20 °C long term, protect from heat, moisture and light |
The product page states that its certificates cover a batch-specific HPLC purity figure, sequence and identity confirmation, a lot number and analytical test date, and the form and storage statement. The COA page lists the published ones. Where the page shows a lot document for a given lot, that is the document to compare with your label; where it does not, the absence is itself information to record.
Why a proline-rich 15-mer can give a messy chromatogram
BPC-157 has four proline residues, three of them in a row (Pro-Pro-Pro) near the N-terminal end. Proline is the only proteinogenic residue whose peptide bond readily exists in both cis and trans forms, and in some peptides the slow interconversion of those forms shows up as a broadened or partly split peak on reversed-phase HPLC. That is a property of the method and the sequence, not necessarily an impurity. It is a reason to ask what the chromatogram looks like rather than to accept the percentage alone, and a reason why two laboratories can report slightly different peak shapes for the same material at different temperatures.
Three impurity types deserve specific attention.
- Deletion sequences. Short peptides are straightforward to synthesize, but a missed coupling gives a fourteen-residue relative. Solid-phase synthesis builds the chain one residue at a time and the methods literature describes standard Fmoc procedures and the special techniques needed when the growing chain aggregates (Coin and colleagues, 2007; Behrendt and colleagues, 2016). A run of three prolines and an Asp-Asp pair are places where a careful chemist checks the coupling.
- Aspartyl modifications. The sequence has two adjacent aspartic acid residues. Aspartyl residues in peptides can form a cyclic succinimide intermediate and rearrange to isoaspartyl forms, a reaction type reviewed for decades (Geiger and Clarke, 1987). Such isomers have identical mass to the target, so a mass result will not distinguish them; only separation can.
- Residual cleavage reagents and counter-ions. Peptides are normally delivered as salts, most often trifluoroacetate unless exchanged (Sikora and colleagues, 2020). This does not change the HPLC percentage, but it changes the weight of peptide per mg of powder.
Because the molecule contains no cysteine, methionine or tryptophan, the common oxidation and disulfide problems seen with other peptides are not the usual concern here.
What the identity line can and cannot prove
The statement "identity confirmed" has several possible meanings: an observed mass, a retention-time match to a reference standard, a sequence confirmation by fragmentation, or a statement by the manufacturer that the synthesis followed the sequence. Each is evidence of a different strength. A mass match shows the elemental composition is right, not the order of residues; two peptides that are permutations of one another have the same mass. Fragmentation data or comparison with a reference standard speaks to order. Ask what was done, not only whether it was called a confirmation.
The product page lists "sequence / identity confirmation" among the certificate contents. That is a promise about the category of information. Check the actual line against the list above.
Arithmetic you will do with the certificate in hand
Once the lot and purity are accepted, the next job is to record how the stock will be made. For a 10 mg vial, concentration is c = m / V, with m the declared mass and V the diluent volume; for molar concentration use cM = (m / MW) / V, with MW the molar mass of the peptide from your own formula calculation. If the certificate reports peptide content as a fraction p, multiply the mass by p. The calculator and the volume calculation guide do this for you. Write the result and the lot string together on the vial label.
Receiving checks that complement the certificate
| Step | Purpose | Record |
|---|---|---|
| Match label to certificate | Traceability | Lot string, date of comparison, initials |
| Inspect vial and cake | Detect transport damage or moisture | Seal intact, solid colour, any collapse |
| Move to the stated storage tier | Preserve the measured quality | Date, location, temperature |
| Dissolve and look | Gross quality screen | Clear and colourless or not; time to dissolve |
| Optional in-house HPLC or LC-MS | Independent confirmation | Method, retention, observed mass |
BPC-157 dissolves readily in water-based diluents according to the product page, and there is no need to shake it. The general procedure is in how to reconstitute a lyophilized peptide, and room-temperature questions are discussed in BPC-157 room temperature stability.
Reading someone else's certificate critically
Several patterns appear on peptide certificates of every compound and are worth recognizing.
- A purity number with no chromatogram. You cannot judge peak shape or minor peaks.
- A chromatogram with no lot string. It cannot be tied to the vial.
- A round figure on every lot. Real measurements vary from lot to lot, and a number that never moves deserves a question.
- A test date long before the lot was made. It suggests the document describes something else.
- A mass reported to a precision the instrument could not deliver. Observed and calculated masses should be shown with an error consistent with the method.
- No statement of salt form or peptide content. The declared milligrams may not be peptide base.
The principles of chromatographic purity are explained in understanding HPLC purity, and independent testing is described in third-party testing explained. The sibling article BPC-157 purity testing covers the methods themselves.
What the literature does not supply
The published work on BPC-157 is largely preclinical and has been reviewed in the musculoskeletal context (Gwyer and colleagues, 2019). None of it defines an impurity specification for a research-grade vial, and none reports on the commercial lots cited here. The expectations in this article come from general peptide analytical practice, and a laboratory with a stricter requirement should set its own limit and test against it. Stability data for reconstituted material are also limited, so general principles apply: the dry state is far more stable than solution and lower temperature slows chemical change (Manning and colleagues, 2010).
Related reading
- BPC-157 research overview
- BPC-157 purity testing
- Where to buy BPC-157 for research
- How to read a COA
- BPC-157 product page
Frequently asked questions
What should a BPC-157 certificate of analysis contain?
At minimum the compound name and sequence, a lot number that matches the vial, an analytical date, the HPLC method and purity, a chromatogram, and an identity result. The product page also lists form and storage.
Why can a proline-rich peptide look split on HPLC?
Proline peptide bonds interconvert between cis and trans forms, and in some methods that shows up as a broadened or partly split peak. It is a feature of the method, not always an impurity, which is why the chromatogram matters.
Does a mass match prove the sequence is right?
It proves the composition. Peptides with the same residues in a different order have the same mass, so order needs fragmentation data or comparison with a reference standard.
Can HPLC and mass spectrometry detect aspartyl isomers?
Mass cannot, because isoaspartyl forms have the same mass. A good separation can sometimes resolve them, but a standard gradient may not.
What is the declared mass of a vial?
It is the quantity of material declared on the label. Counter-ion and water mean it is not automatically peptide base, so peptide content matters for exact molar work.
How do I calculate stock concentration?
Use c = m / V for mg/mL and c = (m / MW) / V for molar concentration, multiplying m by the peptide content fraction if it is reported. The calculator page does the arithmetic.
How is lyophilized BPC-157 stored?
The product page states 2–8 °C, with −20 °C for long-term storage, and protection from heat, moisture and light.
Does BPC-157 contain oxidation-prone residues?
The sequence has no methionine, cysteine or tryptophan, so the usual oxidation and disulfide concerns are not the main ones. Aspartyl rearrangement and deletion sequences are the more relevant issues.
What if a lot has no published certificate?
Record that in the receiving log, check the COA page for later updates, and run an in-house identity and purity check if the result of the experiment depends on it.
Is BPC-157 from V8 for use in humans or animals?
No. It is supplied for laboratory research use only.
Related reading: BPC-157 Introduction: How to Read the Research, Ordering BPC-157 and TB-500: Lab Planning Guide.
References
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
- Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247-3256. doi:10.1038/nprot.2007.454
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. doi:10.1016/S0021-9258(19)75855-4
- Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals (Basel). 2020;13(12):442. doi:10.3390/ph13120442
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
